Silence Therapeutics (SLN) EBITDA Margin (2024 - 2026)
Silence Therapeutics (SLN) posted EBITDA Margin of 3729.15% for Q1 2026, up 89.82% sequentially from 36650.0% in Q4 2025, and up 1627719.0% YoY from N/an in Q1 2025.
Silence Therapeutics (SLN) EBITDA Margin (2024 - 2026) Analysis & Trends
Silence Therapeutics has reported EBITDA Margin for 3 years, with the latest figure at 3729.15% in Q1 2026.
- Quarterly EBITDA Margin rose 1627719.0% year-over-year to 3729.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9345.05% (down 903456.0% YoY) and the FY2025 annual result came in at 16292.84%, down 1614647.0% from the prior year.
- EBITDA Margin rose to 3729.15% in Q1 2026 per SLN's latest filing, from 36650.0% in the prior quarter.
- Over five years, EBITDA Margin peaked at 17.2% in Q4 2024 and troughed at 36650.0% in Q4 2025.
- A 3-year average of 10285.29% and a median of 3729.15% in 2026 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin tumbled 3663280 bps in 2025, then jumped 1627719 bps in 2026.
- Over 3 years, EBITDA Margin stood at 17.2% in 2024, then sank by 213004 bps to 36650.0% in 2025, then surged by 90 bps to 3729.15% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 3729.15%, 36650.0%, and 16505.66% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,729.15% |
| Dec 31, 2025 | -36,650.00% |
| Sep 30, 2025 | -16,505.66% |
| Jun 30, 2025 | -10,697.77% |
| Mar 31, 2025 | -20,006.34% |
| Dec 31, 2024 | -17.20% |
| Sep 30, 2024 | -2,002.47% |
| Jun 30, 2024 | -2,923.50% |
| Mar 31, 2024 | -35.55% |